SMMT News and Press, Summit Therapeutics Inc.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. “It is an honor to add Jeff Huber to our excellent, diverse group of...

2024-06-24 06:35:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks und...

2024-06-17 16:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-17 05:50:00 ET Never ignore the power of momentum. Sometimes the fastest-moving objects are the ones that keep on racing ahead. That could be the case with a select group of stocks that have delivered tremendous gains this year. These three stocks have soared 179% or more so far...

2024-06-09 05:15:00 ET Summary Structure Therapeutics raises $476 million through an offering of its ADSs after announcing positive clinical results for its obesity drug. Suzhou Alphamab Oncology partners with ArriVent BioPharma to develop antibody drug conjugates, potentially rec...

2024-06-08 10:19:36 ET More on AstraZeneca, Bristol-Myers, etc. Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript) Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly ...

2024-06-03 06:18:24 ET More on Summit Therapeutics Summit Therapeutics Stock: Plunging Despite A Win? Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer Summit lead asset app...

$200 Million in Net Proceeds Raised at Premium to Previous Closing Price In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to include Latin America, Middle East, and Africa Expansion Is in Addition to Existing License Territories of US...

2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...

2024-06-01 14:44:45 ET More on etc. ARKK - Risky Does Not Equal Reward Canadian Tire Offers A Good Earnings Yield Despite Temporary Slowdown DAPP: Crypto Stocks Lose Some Luster In 2024 As New ETFs Capture The Spotlight Delta summer demand 'quite healthy' - C...